Dry Eye Disease
Dry eye disease has undergone a major shift in how it is understood and treated over the past decade. Once considered a minor inconvenience managed primarily with artificial tears, it is now recognised as a complex, multifactorial disorder involving tear film instability, ocular surface inflammation, and neurosensory dysfunction. This evolving understanding has led to more sophisticated and targeted management strategies, with current approaches in 2025 emphasizing disease modification rather than simple symptom relief.
Optometrists can now distinguish between key subtypes of the condition, particularly aqueous-deficient dry eye, in which tear production is reduced, and evaporative dry eye, most commonly linked to meibomian gland dysfunction. Rather than applying a uniform treatment to all patients, therapy is increasingly tailored to the underlying cause, often combining treatment to restore tear film stability and improve long-term ocular surface health.
Newer medications targeting specific aspects of the disease process are now commonly used. Anti-inflammatory treatments remain a cornerstone, reflecting the central role of chronic inflammation in dry eye. Medications such as cyclosporine work by modulating immune pathways and improving tear production over time. Short courses of topical corticosteroids are also used to control acute exacerbations. Emerging therapies, including neurostimulatory agents that enhance natural tear secretion and nanotechnology-based drug delivery systems, suggest a future in which treatment is both faster-acting and more precisely targeted.
Alongside pharmacological advances, device-based therapies have become increasingly important, especially in the management of meibomian gland dysfunction. Thermal pulsation systems apply controlled heat and pressure to the eyelids to clear obstructed glands and restore lipid flow, thereby improving tear film stability.
Another important area of development is tear retention. Punctal occlusion, using plugs or longer-lasting fillers, helps conserve existing tears on the ocular surface. In more severe cases, biologic therapies such as autologous serum eye drops have emerged as highly effective options. Derived from the patient’s own blood, these drops contain growth factors and anti-inflammatory components that promote healing of the ocular surface. Related therapies, including platelet-rich plasma and umbilical cord serum, are being explored for their regenerative potential, particularly in refractory disease.
Despite these technological and pharmacological advances, lifestyle and environmental modifications remain a fundamental part of management. Increased screen use has made digital eye strain a major contributor to dry eye symptoms, and simple measures such as regular breaks, conscious blinking, and optimizing humidity can have a meaningful impact. Eyelid hygiene, including warm compresses and lid cleansing, continues to play a key role, particularly in patients with blepharitis or meibomian gland dysfunction. Nutritional interventions, such as omega-3 fatty acid supplementation, may also provide additional anti-inflammatory benefits, although evidence remains mixed.
In summary, dry eye management in 2025 reflects a paradigm shift from palliative care to targeted, disease-modifying therapy. With a growing range of pharmacological agents, procedural interventions, and regenerative treatments, clinicians are now better equipped than ever to address the underlying mechanisms of the disease. This integrated and personalised approach offers improved outcomes and represents a significant advancement in the care of patients with dry eye disease.